Waters (WAT) At $193.79 Forms Top; ACADIA Pharmaceuticals Inc. (ACAD) Had 9 Analysts Last Week

Waters Corporation (WAT) formed multiple top with $211.23 target or 9.00% above today’s $193.79 share price. Waters Corporation (WAT) has $15.41B valuation. The stock decreased 0.38% or $0.73 during the last trading session, reaching $193.79. About 227,342 shares traded. Waters Corporation (NYSE:WAT) has risen 30.08% since December 26, 2016 and is uptrending. It has outperformed by 13.38% the S&P500.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was reinitiated by Ladenburg Thalmann on Thursday, February 2 with “Buy”. JP Morgan maintained the stock with “Buy” rating in Friday, September 4 report. The rating was maintained by Jefferies on Thursday, July 27 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Piper Jaffray on Wednesday, August 9. As per Monday, September 4, the company rating was maintained by Jefferies. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Thursday, October 5 by J.P. Morgan. The company was maintained on Tuesday, October 10 by Jefferies. The firm earned “Neutral” rating on Friday, August 7 by Piper Jaffray. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Thursday, August 27 to “Neutral” rating. See ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) latest ratings:

13/11/2017 Broker: Cowen & Co Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $60.0 Maintain
07/11/2017 Broker: Cowen & Co Rating: Buy New Target: $46.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
04/10/2017 Broker: Cowen & Co Rating: Buy New Target: $46.0 Maintain
05/10/2017 Broker: J.P. Morgan Rating: Buy New Target: $50.0 Maintain
05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $60.0 Maintain
05/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $61.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $49.0 Maintain

Among 15 analysts covering Waters Corporation (NYSE:WAT), 5 have Buy rating, 0 Sell and 10 Hold. Therefore 33% are positive. Waters Corporation has $205.0 highest and $123 lowest target. $175.64’s average target is -9.37% below currents $193.79 stock price. Waters Corporation had 46 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 28 by Leerink Swann. The stock of Waters Corporation (NYSE:WAT) earned “Outperform” rating by Leerink Swann on Thursday, November 10. On Monday, December 4 the stock rating was upgraded by Morgan Stanley to “Equal-Weight”. Jefferies maintained it with “Hold” rating and $188.0 target in Friday, October 20 report. The firm earned “Outperform” rating on Friday, January 6 by William Blair. The firm has “Buy” rating given on Monday, October 2 by Robert W. Baird. Mizuho maintained it with “Neutral” rating and $125 target in Wednesday, July 29 report. The firm has “Hold” rating given on Wednesday, December 20 by Cowen & Co. As per Thursday, August 31, the company rating was maintained by Jefferies. As per Wednesday, April 26, the company rating was maintained by Cantor Fitzgerald.

Investors sentiment decreased to 0.99 in Q3 2017. Its down 0.09, from 1.08 in 2017Q2. It dropped, as 36 investors sold Waters Corporation shares while 163 reduced holdings. 48 funds opened positions while 150 raised stakes. 73.71 million shares or 3.26% more from 71.38 million shares in 2017Q2 were reported. Generation Invest Mngmt Ltd Liability Partnership reported 853,925 shares. 73,560 are held by State Of Wisconsin Board. 33,158 were accumulated by Pub Employees Retirement Systems Of Ohio. Citadel Advsrs Ltd Limited Liability Company owns 34,989 shares for 0% of their portfolio. First Mercantile Trust holds 3,600 shares or 0.12% of its portfolio. Alps Advisors Inc reported 2,476 shares. Deutsche Bancorporation Ag holds 0.02% or 192,401 shares in its portfolio. 401,958 are held by Beck Mack Oliver Ltd Liability. Ballentine Ptnrs Llc holds 0.02% of its portfolio in Waters Corporation (NYSE:WAT) for 2,316 shares. Brown Capital Mgmt Limited Liability Corporation holds 0.01% or 3,123 shares. Manufacturers Life Insurance The stated it has 84,951 shares or 0.02% of all its holdings. Andra Ap invested in 0.12% or 27,600 shares. Pictet Cie (Europe) Sa owns 0.14% invested in Waters Corporation (NYSE:WAT) for 5,500 shares. Ghp Invest Advisors Incorporated has invested 0.19% in Waters Corporation (NYSE:WAT). Rockefeller Service reported 0% stake.

Since August 8, 2017, it had 0 insider purchases, and 6 insider sales for $23.37 million activity. Another trade for 3,500 shares valued at $628,845 was made by KUEBLER CHRISTOPHER A on Tuesday, August 8. Kelly Terrence P sold 25,000 shares worth $4.94M. $4.71M worth of stock was sold by Cassis Eugene G on Wednesday, December 13. Another trade for 18,400 shares valued at $3.42M was made by Khanna Rohit on Friday, September 8. Another trade for 21,997 shares valued at $4.34M was sold by TERRICCIANO DAVID.

Analysts await Waters Corporation (NYSE:WAT) to report earnings on January, 23. They expect $2.44 earnings per share, up 10.41% or $0.23 from last year’s $2.21 per share. WAT’s profit will be $194.06 million for 19.86 P/E if the $2.44 EPS becomes a reality. After $1.77 actual earnings per share reported by Waters Corporation for the previous quarter, Wall Street now forecasts 37.85% EPS growth.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.63 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

Since August 9, 2017, it had 0 buys, and 3 insider sales for $2.96 million activity. 14,322 shares were sold by Baity Glenn, worth $499,534.

The stock increased 1.77% or $0.51 during the last trading session, reaching $29.26. About 1.33 million shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since December 26, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.

Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.04, from 1.05 in 2017Q2. It is negative, as 25 investors sold ACADIA Pharmaceuticals Inc. shares while 58 reduced holdings. 32 funds opened positions while 52 raised stakes. 113.55 million shares or 1.98% less from 115.85 million shares in 2017Q2 were reported. Goldman Sachs Gru stated it has 0.02% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Federated Invsts Incorporated Pa reported 96,399 shares or 0.01% of all its holdings. Tocqueville Asset Limited Partnership invested 0.02% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Hwg Holdings Lp holds 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 460 shares. 87,795 were reported by Dimensional Fund Advisors L P. Citadel Limited Liability Com accumulated 77,212 shares. Knott David M invested in 550 shares. D E Shaw And Company invested in 18,429 shares. Creative Planning accumulated 0.01% or 47,811 shares. California State Teachers Retirement holds 0.01% or 155,504 shares in its portfolio. Morgan Stanley holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 363,392 shares. Advsrs Asset Mgmt has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Dekabank Deutsche Girozentrale holds 0.02% or 68,900 shares. Manufacturers Life The invested in 4,380 shares or 0% of the stock. Alps stated it has 120,544 shares.